Senores Pharmaceuticals Limited has informed the exchange regarding Investor Presentation for Q1FY27

Date: July 27, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Investor Presentation for Q1FY27 Dear Sir/Madam, In terms of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our intimation dated July 21, 2026 regarding the Earnings Conference Call, we enclose herewith the Investor Presentation for Q1FY27. The aforesaid information is also being hosted on the Company's website at www.senorespharma.com. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Enclosure : As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Investor Presentation July 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of,or any omissionfrom,this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible forsuch third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Financial & Operational Highlights Q1 FY27 Private & Confidential Key Highlights Q1FY27 • Consistently delivering robust performance with Revenues for Q1FY27 growing by 36% Y-o-Y • Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of 42% & 30% respectively on a Y-o-Y basis • EBIDTA for Q1FY27 grew by 87% with margin expansion of ~800 bps on a Y-o-Y basis • Robust addition in approved and pipeline products providing high growth visibility for years to come • Steady focus on manufacturing & cost efficiency enabling sustainable margin growth & expansion • Robust & diversified business model supported by Strong & Experience AmerisynLLC management team (A subsidiary of Senores Pharmaceuticals Inc.) Regulated Market Owned Product Portfolio & Visibility Owned ANDAs Corresponding ANDA Products* Huge Opportunity Q1FY26 Q1FY27 Q1FY26 Q1FY27 58 187 Approved ANDAs 30 70 Scaled up Own ANDAs by 2x and Corresponding ANDA products by nearly 2.5x over the past 12 months 23 51 Commercialized 12 24 ANDAs 35 ANDAs with Corresponding 35 136 136 ANDA Productsto be 18 46 Yet To Launch launched with our target share of USD 740 mn+ (gross) ANDAs Under 39 119 Robust Pipeline under 31 57 development of 39 molecules Pipeline with 119 unique strengths *ANDA Products represents individual strengths associated with an ANDA 5 CDMO / CMO & Emerging Market Opportunity Products Corresponding ANDA Products* Huge Opportunity Q1FY26 Q1FY27 Q1FY26 Q1FY27 CDMO/CMO business focused on specialty, government supplies CDMO/ CMO and controlled substances. 16 34 Commercialized 15 27 Uniquely positioned in USA & Products India to provide end-to-end solutions from development to commercialization. 37 120 Significantly enhances efficiency, CDMO / CMO 15 53 scale & utilization, leading to Pipeline Products better operating leverage. Approved Products Products under Registration Significant expansion of the 513 942 Approved and Pipeline product 450 478 824 858 904 portfolio across 40+ countries Emerging Markets 394 719 308 creating a strong runway for Portfolio future growth. Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Regulated Markets Emerging Markets *ANDA Products represents individual strengths associated with an ANDA 6 Consolidated Financial Highlights – Q1 FY27 Revenue (₹ Crs) EBITDA (₹ Crs) PAT (₹ Crs) 36% 87% 56% 180.2 53.8 30.7 132.6 19.7 28.8 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Gross Margin (%) EBITDA Margin (% ) PAT Margin (%) +980 bps +810 bps +220 bps 63.5% 29.8% 17.0% 53.7% 14.9% 21.7% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Segmental Financial Highlights – Q1 FY27 Segment Revenue (₹ Crs) Q1FY27 Q1FY26 Y-o-Y FY26 FY25 Y-o-Y Regulated Markets 127.8 90.1 41.9% 427.4 244.8 74.6% Emerging Markets 37.6 29.0 29.6% 145.0 121.2 19.7% Branded Generics 8.0 8.2 -2.4% 40.0 8.2 385.3% Others (Incl. API Sales) 6.8 5.2 29.2% 20.3 36.2 -43.9% Total Revenue 180.2 132.6 35.9% 632.6 410.4 54.1% • Regulated Markets - EBIDTA Margin for Q1 FY27 stood at ~40%. Regulated Markets contributed to 71% of total revenue in Q1FY27 • Emerging Markets - EBIDTA Margin for Q1 FY27 stood at ~14%. Emerging Markets contributed 21% of total revenue in Q1FY27 Consolidated Profit & Loss Account – Q1 FY27 Consolidated P&L (₹ Crs) Q1 FY27 Q1 FY26 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 180.2 132.6 35.9% 632.6 410.3 54.2% Cost of Goods Sold 65.7 61.4 251.7 180.7 Gross Profit 114.5 71.3 60.6% 381.0 229.6 65.9% Gross Margin (%) 63.5% 53.7% 980 bps 60.2% 56.0% 420 bps Employee Cost 29.9 21.7 112.3 60.4 Other Expenses 30.8 20.8 100.4 67.5 EBITDA 53.8 28.8 87.0% 168.3 101.8 65.3% EBITDA Margin (%) 29.8% 21.7% 810 bps 26.6% 24.8% 180 bps Other Income 2.8 8.7 47.1 7.2 Depreciation 9.9 6.0 31.3 16.8 Finance Cost 7.2 5.0 25.0 21.6 PBT 39.5 26.5 48.9% 159.1 70.6 125.3% Tax Charge / (Credit) 9.0 5.3 37.6 12.2 Profit after Tax 30.4 21.2 43.7% 121.5 58.3 108.4% PAT Margin (%) 16.9% 16.0% 90 bps 19.2% 14.2% 500 bps Minority Interest -0.3 1.5 6.2 -0.2 Profit a [Showing first 8,000 characters — download PDF for full document]